Insights into the pathological basis of dementia from population‐based neuropathology studies
Neuropathology and Applied Neurobiology · 2023-08 · 49 (4)
DOI: 10.1111/nan.12923 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Neuropathology and Applied Neurobiology, online erschienen am 06.08.2023. Verfasst von Stephen B Wharton und 7 weiteren Autor:innen. Beteiligte Einrichtung: Sheffield Institute for Translational Neuroscience, University of Sheffield, Sheffield, UK. Hauptthemen laut MEDLINE: Alzheimer Disease, Tauopathies. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 158 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council, Department of Health, Alzheimer's Society.
Themen: Demenz
Abstract (Originalsprache)
The epidemiological neuropathology perspective of population and community‐based studies allows unbiased assessment of the prevalence of various pathologies and their relationships to late‐life dementia. In addition, this approach provides complementary insights to conventional case–control studies, which tend to be more representative of a younger clinical cohort. The Cognitive Function and Ageing Study (CFAS) is a longitudinal study of cognitive impairment and frailty in the general United Kingdom population. In this review, we provide an overview of the major findings from CFAS, alongside other studies, which have demonstrated a high prevalence of pathology in the ageing brain, particularly Alzheimer's disease neuropathological change and vascular pathology. Increasing burdens of these pathologies are the major correlates of dementia, especially neurofibrillary tangles, but there is substantial overlap in pathology between those with and without dementia, particularly at intermediate burdens of pathology and also at the oldest ages. Furthermore, additional pathologies such as limbic‐predominant age‐related TDP‐43 encephalopathy, ageing‐related tau astrogliopathy and primary age‐related tauopathies contribute to late‐life dementia. Findings from ageing population‐representative studies have implications for the understanding of dementia pathology in the community. The high prevalence of pathology and variable relationship to dementia status has implications for disease definition and indicate a role for modulating factors on cognitive outcome. The complexity of late‐life dementia, with mixed pathologies, indicates a need for a better understanding of these processes across the life‐course to direct the best research for reducing risk in later life of avoidable clinical dementia syndromes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Sheffield Institute for Translational Neuroscience, University of Sheffield, Sheffield, UK.
- Population Health Sciences Institute, Newcastle University, Sheffield, UK.
- Cambridge Public Health, School of Clinical Medicine, University of Cambridge, Sheffield, UK.
ORCID-Profile: Stephen B Wharton, Julie E Simpson
Förderung
- Medical Research Council
- Department of Health
- Alzheimer's Society
Zitieren
APA
Wharton, S. B., Simpson, J. E., Ince, P. G., Richardson, C. D., Merrick, R., Matthews, F. E., Brayne, C., & CFAS (2023). Insights into the pathological basis of dementia from population‐based neuropathology studies. Neuropathology and Applied Neurobiology, 49(4). https://doi.org/10.1111/nan.12923
Vancouver
Wharton SB, Simpson JE, Ince PG, Richardson CD, Merrick R, Matthews FE, et al. Insights into the pathological basis of dementia from population‐based neuropathology studies. Neuropathology and Applied Neurobiology. 2023;49(4). doi:10.1111/nan.12923
BibTeX
@article{Wharton2023,
author = {Wharton, Stephen B and Simpson, Julie E and Ince, Paul G and Richardson, Connor D and Merrick, Richard and Matthews, Fiona E and Brayne, Carol and CFAS, CFAS},
title = {Insights into the pathological basis of dementia from population‐based neuropathology studies},
journal = {Neuropathology and Applied Neurobiology},
year = {2023},
volume = {49},
number = {4},
doi = {10.1111/nan.12923}
}
EUVIMED